In the latest session, Agile Therapeutics Inc (NASDAQ: AGRX) closed at $0.71 down -3.15% from its previous closing price of $0.73. In other words, the price has decreased by -$0.0280 from its previous closing price. On the day, 13660059 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of Agile Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.44 and its Current Ratio is at 0.57.
On November 29, 2018, Maxim Group started tracking the stock assigning a Buy rating and target price of $3.Maxim Group initiated its Buy rating on November 29, 2018, with a $3 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AGRX now has a Market Capitalization of 2.11M and an Enterprise Value of 7.17M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.10. Its current Enterprise Value per Revenue stands at 0.09 whereas that against EBITDA is -0.15.
Stock Price History:
Over the past 52 weeks, AGRX has reached a high of $14.50, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is 1.2721, while the 200-Day Moving Average is calculated to be 2.1225.
Shares Statistics:
For the past three months, AGRX has traded an average of 364.70K shares per day and 1.52M over the past ten days. A total of 2.96M shares are outstanding, with a floating share count of 2.85M. Insiders hold about 3.90% of the company’s shares, while institutions hold 8.53% stake in the company. Shares short for AGRX as of Feb 29, 2024 were 222.1k with a Short Ratio of 0.61, compared to 189.89k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.49% and a Short% of Float of 7.50%.
Earnings Estimates
There are 1 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.54 for the current quarter, with a high estimate of -$0.54 and a low estimate of -$0.54, while EPS last year was -$5. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$7.6 and -$7.6 for the fiscal current year, implying an average EPS of -$7.6. EPS for the following year is $0.66, with 1 analysts recommending between $0.66 and $0.66.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $9.2M this quarter.It ranges from a high estimate of $9.2M to a low estimate of $9.2M. As of the current estimate, Agile Therapeutics Inc’s year-ago sales were $4M, an estimated increase of 130.20% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $9.21M, an increase of 170.90% over than the figure of $130.20% in the same quarter last year. There is a high estimate of $9.21M for the next quarter, whereas the lowest estimate is $9.21M.
A total of 1 analysts have provided revenue estimates for AGRX’s current fiscal year. The highest revenue estimate was $25.28M, while the lowest revenue estimate was $25.28M, resulting in an average revenue estimate of $25.28M. In the same quarter a year ago, actual revenue was $10.84M, up 133.20% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $42.86M in the next fiscal year. The high estimate is $42.86M and the low estimate is $42.86M. The average revenue growth estimate for next year is up 69.50% from the average revenue estimate for this year.
